Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
December 01 2021 - 8:11AM
InvestorsHub NewsWire
Pasithea
Therapeutics Expands
its Mobile Clinics into Florida and Nevada
-- Pasithea Clinics commences in-home IV ketamine infusion
therapy in Florida and Nevada --
-- Treatments conducted by board-certified medical
professionals --
-- Expansion to additional U.S. cities in coming months
--
Miami Beach, FL / December 1, 2021 -- InvestorsHub NewsWire
-- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a novel
biotechnology company focused on the research and discovery of new
and effective treatments for psychiatric and neurological
disorders, today announced that Pasithea Clinics, its wholly owned
subsidiary, has expanded the availability of its intravenous ("IV")
ketamine therapy to patients in Florida and Nevada. Ketamine was
introduced to the medical community as an anesthetic more than 50
years ago and in sub-anesthetic doses has shown remarkable efficacy
in the treatment of certain psychiatric conditions, such as
treatment-resistant depression ("TRD") and post-traumatic stress
disorder ("PTSD").
"In November, we opened our first U.S. mobile clinics in New
York and California, and we're pleased to announce that our in-home
IV ketamine infusion therapy is now available in Nevada and
Florida," said Dr. Tiago Reis Marques, CEO of Pasithea
Therapeutics. "The pandemic has exacerbated the mental health
crisis and the number of patients suffering from depression
increased by approximately 25% in the past year. Today, up to three
million Americans are known to have a diagnosis of
treatment-resistant depression. These patients often struggle to
complete day-to-day activities, and the effort required to visit a
physical clinic can feel overwhelming. By expanding access to
in-home treatment, we aim to close the treatment gap. Initially,
the treatment will be offered in Miami and Las Vegas and will
expand to other cities in these states in the coming weeks.
Pasithea mobile clinics are already available in New York City, Los
Angeles, San Diego, and San Francisco."
"The efficacy of ketamine in improving symptoms of some
mental health disorders is well documented, and our mobile clinics
enable patients to receive therapy in the privacy and comfort of
their own homes while still under the care of an experienced
medical team. This type of program can be crucial for people who
struggle with treatment-resistant depression and is an important
step in expanding access to IV ketamine treatment. We look forward
to continuing our U.S. expansion in the coming months," concluded
Dr. Adam Nadelson, Managing Director of Pasithea Clinics in the
United States.
Studies have shown that up to 70% of those who receive IV
ketamine treatment will eventually show a clinical response. While
the number of treatments suggested is done on a case-by-case basis,
a typical treatment plan consists of up to six infusions over a
period of
two to three weeks.
About Pasithea
Therapeutics Corp.
Pasithea Therapeutics
Corporation is a U.S. biotechnology company focused on the research
and discovery of new and effective treatments for psychiatric and
neurological disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders. Pasithea is also focused on addressing
the needs of patients currently suffering with mental illness by
providing access to IV ketamine infusions both in clinics and
in-home settings.
Forward
Looking Statements
This press release contains statements that constitute
"forward-looking statements." Forward-looking statements are
subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company's filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law.
Pasithea Therapeutics Corp. Company
Contact
Dr. Tiago Reis
Marques
Chief Executive
Officer
E:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M.
Wilson
In-Site
Communications, Inc.
T:
212-452-2793
E:
lwilson@insitecony.com
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pasithea Therapeutics (NASDAQ:KTTA)
Historical Stock Chart
From Sep 2023 to Sep 2024